Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie – GISC. Issue 7 (July 2016)

• Record Type: Journal Article
• Authors: Mazzaro, Cesare; Dal Maso, Luigino; Urraro, Teresa; Mauro, Endri; Castelnovo, Laura; Casarin, Pietro; Monti, Giuseppe; Gattei, Valter; Zignego, Anna Linda; Pozzato, Gabriele
• Is Part Of: Digestive and liver disease. Volume 48:Issue 7(2016)
• Page Start: 780
• Page End: 784
• Publication Date: 2016-07
• Subjects: Cryoglobulinemia -- Entecavir -- Hepatitis B virus -- Vasculitis; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2016.03.018
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background: Cryoglobulinemic vasculitis (CV) related to Hepatitis-B Virus (HBV) is rare and its treatment is ill-defined. Aims: To describe clinical and treatment characteristics of HBV-related CV patients. In addition, the efficacy of treatment with antiviral agent nucleotide (NUC), including Entecavir, Adefovir, and Lamivudine, was explored. Methods: In four Italian centres, 17 HBV-positive CV patients (median age 56 years, range 45–70) were enrolled. Results: The extrahepatic manifestations were: purpura (100%), arthralgias (71%), peripheral neuropathy (29%), chronic hepatitis (47%), liver cirrhosis (29%), and glomerulonephritis (18%). Mixed cryoglobulinemias were type II (88%) and type III (12%). The median cryocrit was 3% (range 1–14), rheumatoid factor was 200 U/L (range 20–5850), C4 was 12 mg/dl (range 2–31), ALT 71 U/L (range 36–114). All patients were HBsAg-positive and 80% anti-HbeAg-positive. At enrollment, they were treated with steroids (eight), Entecavir (five), Alpha-IFN (two), Adefovir and Lamivudine (one each). After NUC treatment, no disease progression was observed and, in all patients, HBV-DNA became undetectable. Moreover, a regression of purpura and a reduction of cryocrit were observed. Four patients died during therapy, two of kidney failure and two of liver cirrhosis. Conclusion: NUC therapy appeared to be safe and effective in CV-related HBV.